Novacyt Cash Flow Conversion Efficiency

Latest as of December 2025: -0.141x

Novacyt cash flow conversion efficiency. Based on the latest financial reports, Novacyt (ALNOV) has a cash flow conversion efficiency ratio of -0.141x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.28 Million ≈ $-3.84 Million USD) by net assets (€23.34 Million ≈ $27.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Novacyt (2009–2025)

Cash flow conversion efficiency of Novacyt from 2009 to 2025. This chart illustrates how Novacyt's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALNOV live share price for real-time trading data and today's change.

Novacyt Cash Flow Conversion Ratio Explained

Novacyt cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Novacyt Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Novacyt ranked by their cash flow conversion efficiency. Also see ALNOV market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Vroom, Inc. Common Stock NASDAQ:VRM	0.151x
Mudajaya Group Bhd KLSE:5085	-0.012x
Yao I Fabric Co Ltd TWO:4430	0.059x
Globe Metals & Mining Ltd AU:GBE	-0.036x
Ocumetics Technology Corp V:OTC	0.022x
Radiant Cash Management Services Limited NSE:RADIANTCMS	-0.014x
Indo Acidatama Tbk JK:SRSN	0.060x
AS Ekspress Grupp F:DYC	-0.002x

Annual Cash Flow Conversion Efficiency for Novacyt (2009–2025)

The table below shows the annual cash flow conversion efficiency of Novacyt from 2009 to 2025. Review Novacyt free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€23.34 Million ≈ $27.29 Million	€-8.76 Million ≈ $-10.24 Million	-0.375x	-111.64%
2024-12-31	€47.88 Million ≈ $55.98 Million	€-8.49 Million ≈ $-9.93 Million	-0.177x	+38.10%
2023-12-31	€87.24 Million ≈ $102.00 Million	€-24.99 Million ≈ $-29.22 Million	-0.286x	-140.40%
2022-12-31	€115.22 Million ≈ $134.70 Million	€-13.73 Million ≈ $-16.05 Million	-0.119x	-207.71%
2021-12-31	€141.81 Million ≈ $165.80 Million	€15.69 Million ≈ $18.34 Million	0.111x	-83.81%
2020-12-31	€150.71 Million ≈ $176.20 Million	€102.98 Million ≈ $120.39 Million	0.683x	+1029.33%
2019-12-31	€12.47 Million ≈ $14.58 Million	€-916.70K ≈ $-1.07 Million	-0.074x	-18.83%
2018-12-31	€18.15 Million ≈ $21.22 Million	€-1.12 Million ≈ $-1.31 Million	-0.062x	+66.82%
2017-12-31	€22.12 Million ≈ $25.86 Million	€-4.12 Million ≈ $-4.82 Million	-0.186x	-29.43%
2016-12-31	€15.15 Million ≈ $17.71 Million	€-2.18 Million ≈ $-2.55 Million	-0.144x	+77.91%
2015-12-31	€6.05 Million ≈ $7.07 Million	€-3.95 Million ≈ $-4.61 Million	-0.652x	-1282.94%
2014-12-31	€14.40 Million ≈ $16.83 Million	€-678.92K ≈ $-793.73K	-0.047x	+92.08%
2013-12-31	€1.80 Million ≈ $2.10 Million	€-1.07 Million ≈ $-1.25 Million	-0.595x	-254.27%
2012-12-31	€1.34 Million ≈ $1.57 Million	€-225.28K ≈ $-263.37K	-0.168x	-121.72%
2011-12-31	€-744.73K ≈ $-870.67K	€-576.20K ≈ $-673.63K	0.774x	+2037.72%
2010-12-31	€-845.81K ≈ $-988.85K	€33.77K ≈ $39.48K	-0.040x	-103.70%
2009-12-31	€-654.03K ≈ $-764.63K	€-705.19K ≈ $-824.44K	1.078x	--

About Novacyt

PA:ALNOV France Medical Devices

Market Cap

$36.87 Million

€31.54 Million EUR

Market Cap Rank

#22844 Global

#357 in France

Share Price

€0.44

Change (1 day)

-1.14%

52-Week Range

€0.32 - €0.90

All Time High

€13.24